You are here

Alzheimer’s Drug Fails to Meet Primary Endpoints in Phase III Trials

But cognitive decline is slowed in some patients (Aug. 24)

However, a prespecified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate AD. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild AD but not in patients with moderate AD.

Adverse events with an incidence of at least 1% that occurred statistically significantly more in the solanezumab group than in the placebo group included lethargy, rash, malaise, and angina.

An ongoing, open-label extension study, EXPEDITION-EXT, will continue as planned.

An independent analysis of the data from the EXPEDITION studies is being performed by the Alzheimer's Disease Cooperative Study (ADCS), an academic national research consortium that facilitates the discovery, development, and testing of new drugs for the treatment of AD. ADCS will present its findings at the American Neurological Association (ANA) meeting in Boston, Mass., on October 8, 2012, and at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Monte Carlo, Monaco, on October 30, 2012.

The next steps for solanezumab have not yet been decided and will be determined after discussions with regulators.

For more information, visit the Eli Lilly Web site.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs